Neuropore Therapies Commences Phase 1 Clinical Trials
Posted on August 12, 2015
Neuropore Therapies Commences Phase 1 Clinical Trials
- Neuropore Therapies Inc. commences Phase 1 clinical trials with NPT200-11; a potential new disease modifying treatment for Parkinson's Disease
- This trial is a randomized, double blind placebo controlled clinical trial designed to evaluate safety, tolerability and pharmacokinetics of NPT200-11 in healthy subjects
San Diego, CA – 12 August 2015 8:01am (EST) –
Neuropore Therapies, Inc. announced today that it has commenced Phase 1 clinical trials with NPT200-11, a novel potential treatment for Parkinson’s Disease.
“We are pleased to have advanced NPT200-11 to first dose in man, a significant milestone in the development of this novel drug candidate. The decision to progress into Phase 1 follows several years of highly promising pre-clinical research,” said Dieter Meier, Neuropore’s CEO. “We believe that NPT200-11 has the potential to become an important advancement in the treatment of Parkinson’s Disease and other synucleinopathies.”
As announced in January 2015, Neuropore Therapies entered into world-wide collaboration with UCB to develop and commercialize NPT200-11 in all indications. To date, Neuropore has received $20.5 million of the potential $460 million in total milestones through its collaboration with UCB.
Neuropore Therapies has conducted extensive research over the last seven years to develop novel therapeutic products aimed at slowing the progression of Parkinson’s disease and related disorders. The results of this effort include NPT200-11. Other scientifically novel approaches with preclinical stage drug-candidates are ongoing.
About Parkinson's Disease
Parkinson’s disease (PD) is the second most common neurodegenerative disorder after Alzheimer’s disease. There are an estimated seven to ten million patients with PD worldwide. Current treatments for PD are effective at managing the early motor symptoms of the disease, mainly through the use of levodopa and dopamine agonists. As the disease progresses and dopaminergic neurons continue to be lost, these drugs eventually become less effective at treating the symptoms.
By stabilizing conformations of alpha-synuclein that are then incapable of assembling into toxic pore-like oligomers in cell membranes, NPT200-11, blocks the pathological protein misfolding, aggregation and deposition that contribute to synaptic dysfunction and cell death in PD and related disorders. NPT200-11 is orally bioavailable, has promising drug-like properties and, has shown robust beneficial actions on multiple endpoints in animal models.
About Neuropore Therapies, Inc.
Neuropore Therapies is developing novel small molecule therapeutics to treat and slow the progression of neurodegenerative disorders such as Alzheimer’s and Parkinson’s disease. The approach being taken by Neuropore is to target an underlying pathological process common to these disorders – the accumulation of toxic oligomeric aggregates of misfolded neuronal proteins in cell membranes. By preventing the formation of these toxic aggregates synaptic function may be restored and neurodegenerative processes slowed.
Neuropore Therapies uses structure-based drug design and dynamic molecular modeling to identify key target regions on proteins that are important for the formation of toxic protein aggregates. Candidate compounds targeting these regions are then synthesized and evaluated in cell-free and cell-based assays systems. Promising compounds are then evaluated in various disease-related animal models.
Forward Looking Statements
This press release contains forward-looking statements based on current plans, estimates and beliefs of management. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, political, regulatory or clinical results and other such estimates and results. By their nature, such forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions which could cause actual results to differ materially from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, product liability claims, challenges to patent protection for products or product candidates, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws and hiring and retention of its employees. UCB is providing this information as of the date of this press release and expressly disclaims any duty to update any information contained in this press release, either to confirm the actual results or to report a change in its expectations.
There is no guarantee that new product candidates in the pipeline will progress to product approval or that new indications for existing products will be developed and approved. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to differences between the partners. Also, UCB or others could discover safety, side effects or manufacturing problems with its products after they are marketed.
Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement.
For Further Information
Media Contact Neuropore:
Dieter Meier, MD
Chief Executive Officer
Phone: +1 858-273-1831